Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study

BackgroundRituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and p...